 |
 |
 |
|
|
||
|
|
Avastin |
|
23 whether to approve avastin for use in treating breast cancer. Whether HDL were separated by precipitation HMP ; or size exclusion chromatography FPLC ; , significantly higher levels of apoC-III and apoE were found in HDL separated from samples stored for 2 weeks at -20oC. Less apoC-III and apoE were recovered in apoBcontaining lipoproteins, particularly TRL. Changes in TRL and HDL apolipoprotein levels were not associated with similar changes in TRL and HDL triglyceride or cholesterol and they were most evident in samples with high TG levels. HDL apoC-III and apoE levels were also significantly higher in plasma samples frozen at -80oC. Even in unfrozen samples stored at 4oC ; , less pronounced yet statistically significant increases were observed in HDL apoC-III and apoE levels after 2 or 6 days of storage. In a previous study carried out in our laboratory 23 ; , we determined the plasma lipoprotein distribution of apoC-III in freshly isolated plasma from normolipidemic NL, n 10 ; and hyperlipidemic n 30 ; subjects. Of the hyperlipidemic subjects, one third n 10 ; were hypertriglyceridemic HTG ; , one third n 10 ; were hypercholesterolemic HC ; , and one third n 10 ; were both HTG and HC. After FPLC separation of plasma lipoproteins, mean SE ; HDL apoC-III concentrations were: 6.9 0.6, 7.6 and 7.2 1.0 mg dl in the NL, HC, HTG and HTG HC groups, respectively 23 ; . In percentage terms, HDL apoC-III represented 54 5%, 46 and 23 3% and of total plasma apoC-III, respectively. These results are shown graphically in Figure 4 relative to plasma TG concentrations. Data for NL and HTG subjects are shown with filled circles and data for HC and HC HTG subjects are shown with empty circles. An inverse relationship clearly exists between the relative amount of plasma apoC-III in HDL and the concentration of total TG, as described by others 27-29 ; . From these data, it can be estimated that individuals - 11 Downloaded from jlr by on March 14, 2008. Dr. Cousins described a novel initiative at Duke University for postmarketing drug surveillance for retinal therapies, particularly for the new anti-VEGF therapies. An important question concerns adverse effects once they have entered the systemic circulation. We know at least some anti-VEGFs circulate; Avastin Genentech, South San Francisco, CA ; injected in one eye can cause a response in the fellow eye. Although no differences in rate of adverse effects appeared in studies comparing treated patients with control subjects, it is possible that a subset of patients with AMD is at risk. Dr. Cousins opined that anti-VEGF trials are not sufficiently powered to identify small but clinically relevant rates of adverse effects. Are retinal physicians good sources of information about adverse drug effects? Probably not, for several reasons. One, patients who feel ill are not likely to contact an eye doctor. They go a family physician or emergency room instead. Two, surveys show that retina specialists tend not to ask patients why they have missed their appointments. Three, according to an informal survey by the American Society of Retina Specialists, their members do not have a tradition of reporting adverse events to the FDA's MedWatch. At Duke, a pilot program is being established that would use a three-pronged approach to adverse-effects reporting: CMS claims analysis, to identify all codes for neovascular AMD, with and without treatment; a Web-based patient registry in which physicians would enroll patients who agree to be contacted about symptoms; and chart audits to validate patient-reported events. The intention is to publish positive and negative findings as a way to provide postmarketing drug surveillance for the community of physicians and patients. Medication Therapy Medications can be used to decrease uric acid levels, thereby decreasing risk of uric acid crystal formation and subsequent renal impairment. Comparison of Uric Acid Lowering Agents. Cheap avastin online
342. BEVACIZUMAB AND CPT-11 IN THE TREATMENT OF RELAPSED MALIGNANT GLIOMA V. Stark-Vance; Neurosciences, Presbyterian Hospital, Dallas, Texas, USA Bevacizumab Avastin ; is a monoclonal antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor VEGF ; . CPT-11 is a semisynthetic camptothecin that binds to and inhibits DNA topoisomerase I, an enzyme necessary for DNA replication. This combination of agents has shown clinical benefit in a clinical trial of metastatic colorectal cancer, while bevacizumab alone was associated with inferior survival in the same population. In phase 2 clinical trials of CPT-11 in patients with recurrent glioma, 4 59 pts demonstrated tumor regression. Some malignant gliomas overexpress VEGF, suggesting that bevacizumab may have clinical activity in this population, possibly increasing the response rate over CPT-11 alone. Between March and December 2004, 21 patients with malignant glioma treated with this combination BC ; were evaluated for treatment response and toxicity. A 6-week cycle consisted of bevacizumab, 5 mg kg, every other week 2, and CPT-11, 125 mg m 2 every week 4, followed by a 2-week rest. MRI scans were obtained after each cycle of treatment. Bevacizumab was not dose-reduced, but CPT-11 doses were reduced for grade 3 or 4 myelosuppression. Of the 21 pts, 11 were GBM and 10 were other high-grade gliomas; median age was 42 3073 ; and median number of prior treatments was 3 210 ; . Toxicities included neutropenia, diarrhea, epistaxis, emesis, and asthenia. One pt died of an intracranial hemorrhage and one pt died of complications of gastrointestinal perforation; both are previously reported toxicities of bevacizumab. Four additional pts died of non-treatment-related complications. Of the 21 pts who could be evaluated for response, there were 1 CR, 8 PRs, and 11 SD. Thirteen pts remain on treatment, 5 after more than 4 cycles. In all pts, radiographic responses were accompanied by reduction in both peritumoral edema and contrast enhancement; most patients who did not meet the criteria for partial response did show clinical and or radiographic improvement. These early results suggest an improvement in response rate and duration of response over treatment with CPT-11 alone and a possible role for bevacizumab in primary therapy for high-grade glioma and avc.
Int.Cl.7 B65D17 32. A TEAR-OFF DEVICE FOR OPENING DRINK CANS. Cavallo, Vincenzo. Phase III trial E4599: carboplatin paclitaxel Avastin Results available PFS and OS superior with the addition of Avastin ; Phase III AVAiL: cisplatin gemcitabine CG ; vs. CG + Avastin 7.5 mg kg q3 weeks vs. CG + Avastin 15 mg kg q3 weeks Trial ongoing Interim data to be submitted H2 '06 for filing purposes only with final E4599 data Phase III chemotherapy + Avastin for 4 cycles followed by Avastin Tarceva maintenance ; ATLAS - recruiting in US Predominant squamous cell histology: Safety trials exploring Avastin + chemotherapy ongoing about to start Treated brain metastases: Safety trial exploring Avastin + chemotx ongoing in US. Avastin reduces abnormal blood vessel growth, stops leakage in the eye and the patients wind up seeing better and bacitracin. Jan 29, 2008 by ed susman orlando, fl - january 29, 2008 - doctors said that the combination of gemcitabine gemzar ; and bevacizumab avastin ; along with radiation in dg news eli lilly q4 profit surges on lower charges, higher sales, volume! Scientific support activities ESA as the FEEP technology is currently foreseen to fly later on the SMART-2, LISA, Gaia, Darwin, Hyper and GOCE missions. A joint CNES ESA AO was prepared by the Project Scientist and released in December 2001 with the aim of Europeanising the payload. Two proposals were received from European institutes and, after careful review by ESA's advisory bodies and the Microscope Project Team, accepted by the SPC in May 2002. ZARM Bremen, D ; proposes to perform free-fall tests of the Microscope accelerometers and to do end-to-end simulations of the EP measurement. The second proposal was submitted by the ESA Project Scientist and deals with extended FEEP testing in orbit in view of the importance of FEEPs for ESA's space science programme. CNES is currently performing the Phase-A study of the mission; the Phase-A review will be held in May 2003. The payload has already passed this review and is now in its detailed design phase. A contract for the procurement of the complete FEEP micropropulsion system has been awarded to Alta Pisa, I ; . The Project Scientist has been nominated as ESA's Directorate of Science representative for the FEEP development and is monitoring this contract in close coordination with ESA's Directorate of Technical and Operational Support. During the development phase, a 1-year endurance test of a flightrepresentative thruster will be carried out. The date for the delivery of the flight propulsion system is set for late 2005; launch is planned for late 2006 and baraclude. FIGURE 2. Skin observations after i.d. injection of LT in complex ganglioside knockout mice. GM2 GD2 synthase knockout KO ; mice or heterozygous Het ; littermates were shaved on the dorsal caudal surface and injected i.d. with 25 l of PBS containing 0.5 g of LT. Swelling of the injection site was measured periodically using calipers up to 2 after injection. A, Skin swelling one day after i.d. injection of LT. Data represent mean SD of 4 mice; , p 0.0005. B and C, Additional mice were injected, and skin biopsies were taken after 2 days of the injection site for histological analyses. Sections were mounted on slides and stained with H&E. LT-injected skin of knockout B ; or heterozygous mice C magnification, 100. As described in Fig. 1, significant dermal edema and inflammatory infiltrates were observed in heterozygous mice but not in the knockout mice. 2 Accounting policies continued Purchases and sales of equity investments are accounted for on the trade date and purchases and sales of other available-for-sale investments are accounted for on settlement date. In 2004 and 2003 equity investments are recorded at cost. Inventories Inventories are included in the financial statements at the lower of cost including raw materials, direct labour, other direct costs and related production overheads ; and net realisable value. Cost is generally determined on a first in, first out basis. Taxation Current tax is provided at the amounts expected to be paid applying tax rates that have been enacted or substantially enacted by the balance sheet date. Deferred tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which the temporary differences can be utilised. Deferred tax is provided on temporary differences arising on investments in subsidiaries, associates and joint ventures, except where the timing of the reversal of the temporary difference can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax is provided using rates of tax that have been enacted or substantively enacted by the balance sheet date. Deferred tax liabilities and assets are not discounted. Derivative financial instruments and hedging 2005 ; Derivative financial instruments are used to manage exposure to market risks from treasury operations. The principal derivative instruments used by GlaxoSmithKline are foreign currency swaps, interest rate swaps and forward foreign exchange contracts. The Group does not hold or issue derivative financial instruments for trading or speculative purposes. Derivative financial instruments are initially recognised in the balance sheet at cost and then remeasured at subsequent reporting dates to fair value. Hedging derivatives are classified on inception as fair value hedges, cash flow hedges or net investment hedges. Changes in the fair value of derivatives designated as fair value hedges are recorded in the income statement, with the changes in the fair value of the hedged asset or liability. Changes in the fair value of derivatives designated as cash flow hedges are recognised in equity. Amounts deferred in equity are transferred to the income statement in line with the hedged forecast transaction. Hedges of net investments in foreign entities are accounted for in a similar way to cash flow hedges and barberry.
37. EAKIN RT, MORGAN LO, GREGGCT, et al: Carbon-l3 nuclear magnetic resonance spectroscopy of living cells and.
A competitor, genzyme cor - baltimore sun, genentech announces full year and fourth quarter 2005 results jan 10, 2006 months ended december 31, 2005 2004 net us product sales rituxan 4, 404 9, 184 herceptin 250, 069 125, avastin 359, 110 190, nutropin products 94, 891 and benzphetamine. In europe, avastin was approved in january 2005 and in the us in february 2004 for the first-line treatment of patients with metastatic colorectal cancer. Peroxisomes of the Ylinp1 strain were fluorescently labeled with genomically encoded Pot1p-GFP. Cells were grown for 16 h in YPD medium, transferred to YPBO medium for 16 h and then visualized at room temperature with a LSM 510 META confocal microscope specially modified for 4D in vivo video microscopy see Materials and Methods ; . Representative frames from Supplemental video 4 show the specific movements of peroxisomes in the Ylinp1 strain. At the start of the video 0' ; , cells already exhibit pseudohyphal characteristics, and peroxisomes are observed in mother cells and preferentially in buds. The cells at left show bidirectional growth. Continued video imaging showed that peroxisomes continue to move from mother cells to buds and localize to bud tips opposite mother cells 30' to 133' ; . Mother cells are largely, but not completely, devoid of peroxisomes. Arrowheads point to tips of mother cells distal to the and avc.
Fed the fiber-free diet. These values were -40% lower than those in freely fed rats in Experiment 1. Table 3 also shows that weights of cecal walls of meal-fed rats were greater than those of the freely fed rats shown in Table 2 ; , and the difference in the weights of cecal walls between the guar gum complex and mixture.
13 prnewswire-firstcall - genentech, inc nyse: ; announced today the publication of data from a pivotal phase iii clinical trial in the new england journal of medicine showing that avastin r ; bevacizumab ; in combination with paclitaxel and carboplatin chemotherapy significantly improved overall survival in patients with unresectable, locally advanced, recurrent or metastatic non-squamous, non- small cell lung cancer nsclc ; , the most common type of lung cancer.
Optical coherence tomography - high-tech retina slit lamp examination in your eye doctor's office avastin injection for macular degeneration visudyne photodynamic therapy for macular degeneration fluorescein angiography - what is it.
Recently, the FDA approved Avastin bevacizumab ; for the treatment of advanced colon cancer. Avastin is a VEGF antagonist made by Genentech. A study was published from the Bascom Palmer Eye Institute in Miami, where Avastin was used in an uncontrolled pilot, open label, study in nine patients with ARMD and subfoveal CNV. The drug is administered by intravenous infusion at two week intervals. Patients in this small study had visual acuity between 20 40 and 20 400 and were treated for 12 weeks. There were reportedly no serious adverse side effects, except a transient mild elevation of blood pressure at 6 weeks, but not at 12 weeks. In study eyes, there was an improvement in median visual acuity scores by 8 letters and mean visual acuity scores by 12 letters. On OCT examination the central retinal thickness decreased by about 160 microns. In fellow eyes the visual acuity also increased, and the retinal thickness measurements also decreased. Fluorescein angiography demonstrated a marked reduction or absence of hyperfluorescence due to the CNV. Since this initial report of the use of Avastin, multiple case series have been reported showing often dramatic resolution of edema in many conditions, including branch vein occlusions, central retinal vein occlusions, diabetic retinopathy, and exudavtive macular degeneration with CNV. We have now had a great deal of experience using it and many of your patients may have benefited from it. Clinical trials may be undertaken to evaluate systemic bevacizumab, either alone or as an adjunct to locally administered VEGF inhibitors as well as photodynamic therapy.
PIPELINE AND THERAPEUTIC PROGRAMS ONCOLOGY PIPELINE HIGHLIGHTS FP1039. Our lead oncology compound, FP1039, is currently undergoing IND-enabling studies. FP1039 uses a novel mechanism to inhibit a pathway that is believed to be a key driver of cancer growth and maintenance. It is a modified receptor that can bind to multiple members within a growth factor family. Activation of this pathway has been correlated with: 1 ; decreased survival and increased risk of metastasis in several major cancers, 2 ; angiogenesis that is resistant to anti-VEGF therapy, and 3 ; cancer initiating cells maintaining their tumorigenicity. In pre-clinical studies, FP1039: Has direct anti-tumor activity in a variety of in vitro and in vivo models, including patient derived xenograft models; Inhibits cancer stem cell proliferation; Reduces the number of metastasis in a lung metastasis model; Strongly inhibits both VEGF and FGF-induced angiogenesis in vivo and Increases the therapeutic effect of targeted therapeutics such as Avastin and Erbitux. June 27, 2003: Bexxar tositumomab and iodine I 131 tositumomab, Corixa Corp. and GlaxoSmithKline ; , a monoclonal antibody-based radioimmunotherapeutic regimen, was approved for the treatment of CD20-positive, follicular non-Hodgkin's lymphoma NHL ; , with or without transformation from a low-grade to a higher grade NHL, in patients whose disease is refractory to rituximab and has relapsed after chemotherapy. Bexxar is a dualaction therapy that pairs a cytotoxic monoclonal antibody tositumomab ; that binds to the CD20 antigen found on NHL cells with radiation therapy Iodine 131 ; . When combined, these agents form a targeted radiolabeled monoclonal antibody that initiates a cytotoxic immune response against CD20-positive NHL cells and also delivers a dose of radiation therapy to these cells. Abbreviated New Drug Applications March 16, 2003: Faulding Pharmaceutical Company received tentative abbreviated new drug application ANDA ; approval for carboplatin for injection, USP 50 mg, 150 mg, and 450 mg single-dose vials ; . Faulding's carboplatin for injection is the generic equivalent of Paraplatin, which is marketed by Bristol-Myers Squibb and under patent until April 2004. Bedford Laboratories received tentative ANDA approval for carboplatin injection, 10 mg mL, on June 6, 2003. June 10, 2003: ESI Lederle received ANDA approval for vinorelbine tartrate injection 10 mg base ; mL, packaged in 10 mg base ; 1 mL and 50 mg base ; 5 mL single-dose vials. Vinorelbine tartrate is the generic equivalent of GlaxoSmithKline's Navelbine, the patent for which expired in July 2002. Fast-Track Designations June 26, 2003: AvastinTM bevacizumab, Genentech, Inc. ; , a vascular endothelial growth factor VEGF ; inhibitor, received a Fast Track designation by the FDA for development as first-line treatment of metastatic colorectal cancer. VEGF is a critical protein involved in tumor angiogenesis; thus, Avastin's antitumor activity is mediated through disruption of tumor blood supply. The FDA granted the Fast Track designation after results of a recent phase III trial demonstrated promising results when Avastin was combined with standard first-line chemotherapy fluorouracil, leucovorin, and irinotecan ; in patients with metastatic colorectal cancer. ODAC Update March 12-13, 2003: The Oncology Drugs Advisory Committee met in March 2003 with plans to discuss progress with phase IV study commitments from the following accelerated approvals of new drug and biologic licensing applications. Meeting minutes are available at : fda.gov ohrms dockets ac 03 transcripts 3936T1 . Doxil doxorubicin HCl, Johnson and Johnson Pharmaceutical Research and Development, L.L.C. ; for 1 ; treatment of acquired immune deficiency syndrome AIDS ; related Kaposi's sarcoma that has progressed after prior combination therapy or in patients intolerant to such therapy and 2 ; treatment of metastatic ovarian cancer in patients whose disease is refractory to both paclitaxel and platinumbased chemotherapy regimens. Ontak denileukin diftitox, Ligand Pharmaceuticals ; for treatment of persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor. Ethyol injection amifostine, MedImmune Oncology, Inc. ; for reducing the cumulative toxicity associated with repeated administration of cisplatin in patients with advanced nonsmall cell lung cancer. In the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan during the 2005-2020 study period, beginning with the launch in 2008 of NXY-059. Analysts believe that the high prevalence of acute ischemic stroke combined with the extensive unmet need for a safe treatment for the disease, and off-label use in the United States, will drive NXY-059 to blockbuster status with sales reaching more than .5 billion in 2020. GENENTECH INC. BEST ONCOLOGY PIPELINE The continued success of Avastin has maintained the overall productivity of biotechnology giant Genentech. Momentum related to this cancer drug and the company's expanding pipeline in this area have earned Genentech gene ; recognition from R&D Directions' editors as having the industry's best oncology pipeline. For the first nine months of 2006, Genentech generated total operating revenue of .57 billion, 38.6% more than in the same period of 2005. Product sales were .4 billion, 38% more than in the first nine months of 2005. Net income grew 61.6% to .52 billion, and earnings per share were .41, 62.1% more than in the same period in 2005. FDA initially approved Avastin Feb. 26, 2004, for metastatic colorectal cancer in combination with intravenous 5-FU-based chemotherapy. Since that approval, Avastin has become one of Genentech's best-selling products. For the first nine months of 2006, Avastin sales were .26 billion, 62.3% more than during the same period in 2005. In October, FDA approved the drug, which comprises bevacizumab, to be used in combination with carboplatin and paclitaxel chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous nonsmall cell lung cancer, . Marketing approval for the new indication was based on results from E4599, a randomized, controlled, multi-center trial that enrolled 878 patients with unresectable, locally advanced, recurrent or metastatic non-squamous nonsmall cell lung cancer. Patients with mixed histology were excluded if the predominant cell type was squamous. Results showed that patients receiving Avastin plus paclitaxel and carboplatin chemotherapy had a 25% improvement in overall survival, the trial's primary endpoint, compared with patients who received paclitaxel and carboplatin alone. One-year survival was 51% in the Avastin plus chemotherapy arm versus 44% in the chemotherapy-alone arm. Median survival of patients treated with Avastin plus chemotherapy was 12.3 months, compared with 10.3 months for patients treated with chemotherapy alone. The E4599 trial was sponsored by the National Cancer Institute, part of the National Institutes of Health, under a cooperative research and development agreement between NCI and Genentech. The trial was conducted by a network of researchers led by the Eastern Cooperative Oncology Group. In November, FDA expanded the approved use of another one of Genentech's best-selling drugs, Herceptin, to include, in combination with other cancer drugs, the treatment of HER2-positive breast cancer after a lumpectomy or mastectomy. FDA granted priority review to the supplemental application for Herceptin. Herceptin is a targeted drug against the HER2 protein on cancer cells. When an excessive amount of HER2 protein is present, the protein causes cancer cells to grow more rapidly and standard chemotherapy may be less effective. In 1998, FDA approved Herceptin for the treatment of metastatic breast cancer. The added approval expands its use to women with cancer only in the breast or lymph nodes that has been removed with surgery. During the first nine months of 2006, Herceptin generated sales of 2 million, 83.5% more than the same period of 2005. "This is especially good news for women who have breast cancer caused by excessive amounts of the HER-2 protein because this cancer typically has a poor prognosis, " says Steven Galson, M.D., director, FDA's Center for Drug Evaluation and Research. The two studies prompting the added indication were conducted by the National Cancer Institute-sponsored Cooperative Groups, a multi-center clinical-trials group. Patients in both trials received standard chemotherapy after surgery for breast cancer. About half the patients were also given Herceptin. The results from both trials, which included information on almost 4, 000 women, were combined and analyzed in 2005. Avastin online |
|
|
© 2005-2007 Online.blackapplehost.com, Inc. All rights reserved.